Simvastatin enhances the antihypertensive effect of ramipril in hypertensive hypercholesterolemic animals and patients. Possible role of nitric oxide, oxidative stress, and high sensitivity C-reactive protein

Fundamental and Clinical Pharmacology

Volumn 26, Issue 6, 2012, Pages 701-711

  Abdel Zaher, Ahmed O ^a   Elkoussi, Alaa Eldin A ^a   Abudahab, Lotfy H ^b   Elbakry, Mohammed H ^c   Elsayed, Elsayed Abu Elwafa ^c  

^a Assiut University Faculty of Medicine   (Egypt)

^b Sohag University   (Egypt)

^c AL AZHAR UNIVERSITY   (Egypt)

Author keywords

Endothelial dysfunction; Oxidative stress; Ramipril; Simvastatin

Indexed keywords

ACETYLCHOLINE; AMINOGUANIDINE; ANGIOTENSIN II; ARGININE; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRITE; RAMIPRIL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; AORTA; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; LIPID BLOOD LEVEL; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RABBIT; RAT; SINGLE DRUG DOSE; SMOOTH MUSCLE CONTRACTILITY; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA, THORACIC; BLOOD PRESSURE; C-REACTIVE PROTEIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; NITRIC OXIDE; OXIDATIVE STRESS; RABBITS; RAMIPRIL; RATS; RATS, WISTAR; SIMVASTATIN; TREATMENT OUTCOME; VASODILATION;

EID: 84867999829     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.00975.x     Document Type: Article

References (46)

1. Tunon J., Martin-Ventura J., Blanco-Colio L.M., Tarin N., Egido J. Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors. Vasc. Health Risk Manag. (2007) 3 521-526.
2. Koh K.K., Oh P.C., Quon M.J. Does reversal of oxidative stress and inflammation provide vascular protection? Cardiovas. Res. (2009) 81 649-659.
3. Kuklinska A.M., Mroczko B., Musial W.J. et al. High-sensitivity C-reactive protein and total antioxidant status in patients with essential arterial hypertension and dyslipidemia. Adv. Med. Sci. (2009) 54 225-232.
4. Chang L., Sun C., Chiang C., Wu C., Chua S., Yip H. Impact of simvastatin and losartan on antiinflammatory effect: in vitro study. J. Cardiovas. Pharmacol. (2007) 49 20-26.
5. Fiorentino A.D., Cianchetti S., Celi A., Dell'Omo G., Pedrinelli A. The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man. Vasc. Health Risk Manag. (2009) 5 233-242.
6. Harrison D., Griendling K.K., Landmesser U., Hornig B., Drexler H. Role of oxidative stress in atherosclerosis. Am. J. Cardiol. (2003) 91 7-11.
7. Wang C.Y., Liu P.Y., Liao J.K. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol. Med. (2008) 14 37-44.
8. Zhou Q., Liao J.K. Pleiotropic effects of statins. Circ. J. (2010) 74 818-826.
9. Kuzelova M., Adameova A., Sumbalova Z. et al. The effect of simvastatin on coenzyme Q and antioxidant/oxidant balance in diabetic-hypercholesterolaemic rats. Gen. Physiol. Biophys. (2008) 27 291-298.
10. Zhou R., Xu Q., Zheng P., Yan L., Zheng J., Dai G. Cardio-protective effect of fluvastatin on isoproterenolinduced myocardial infarction in rat. Eur. J. Pharmacol. (2008) 586 244-250.
11. Won Suh J., Ju Choi D., Jae Chang H. et al. HMG-CoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase. J. Korean Med. Sci. (2010) 25 16-23.
12. Paulsen P. Statins and inflammation: an update. Curr. Opin. Cardiol. (2010) 23 243-275.
13. Tonelli M., Sacks F., Pfeffer M., Lopez-Jimenez F., Jhangri G.S., Curhan G. Effect of pravastatin on blood pressure in peoplewith cardiovascular disease. J. Hum. Hypertens. (2006) 20 560-565.
14. Koh K.K., Michael J., Quon T., Myron A. Are statins effective for simultaneously treating dyslipidemias and hypertension? Atherosclerosis (2008) 196 1-8.
15. Stepien M., Banach M., Mikhailidis D.P., Gluba A., Kjeldsen S.E., Rysz J. Role and significance of statins in the treatment of hypertensive patients. Curr. Med. Res. Opin. (2009) 25 1995-2005.
16. Mancia G., Parati G., Revera M. et al. Statins, antihypertensive treatment, and blood pressure control in clinic and over 24hours: evidence from PHYLLIS randomised double blind trial. BMJ (2010) 340 1197-1201.
17. Ribeiro M.O., Antunes E., de Nucci G., Lovisolo S.M., Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension (1992) 20 298-303.
18. Rauchova H., Ova O.P., Kunes J., Vokurkova M., Ova Z.D., Zicha J. Chronic N-acetylcysteine administration prevents development of hypertension in L-nitro-L-arginine methyl ester-treated rats: the role of reactive oxygen species. Hypertens. Res. (2005) 28 475-482.
19. Angelo E., Rossi P., Tanzi F., Taglietti V. Induction of hypercholesterolemia and mechanism of protection against atherosclerosis. Am. J. Cardiol. (1992) 9 823-831.
20. Friedwald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of LDL-C in plasma without use of preparative ultra-centrifuge. Clin. Chem. (1972) 18 499-502.
21. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Whishnok J.S., Tannenbaum S.R. Analysis of nitrate, nitrite and (15N) In. biological fluids. Anal. Biochem. (1982) 126 131-138.
22. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. (1979) 95 351-358.
23. Roberts W.L., Moulton L., Law T.C. et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin. Chem. (2001) 47 418-425.
24. Kanbay M., Yildirir A., Bozbas H. et al. Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients. Ren. Fail. (2005) 27 297-303.
25. Leibovitz E., Hazanov N., Zimlichman R., Shargorodsky M., Gavish D. Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am. J. Hypertens. (2001) 14 1096-1098.
26. Terzoli L., Mircoli L., Raco R., Ferrari A.U. Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors. J. Cardiovasc. Pharmacol. (2005) 46 310-315.
27. Schmieder R.E., Ruilope L.M. Blood pressure control in patients with comorbidities. J. Clin. Hypertens. (2008) 10 624-631.
28. Steinerova A., Racek J., Stozicky F., Zima T., Fialova L., Lapin A. Antibodies against oxidized LDL-theory and clinical use. Physiol. Res. (2001) 50 131-141.
29. Wang C.H., Li S.H., Weisel R.D. et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation (2003) 107 1783-1790.
30. Vermas S., Wang C.H., Li S.H. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation (2002) 106 913-919.
31. Liu P.Y., Liu Y.W., Lin L.J., Chen J.H., Liao J.K. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation (2009) 119 131-138.
32. Delbosc S., Cristol J., Descomps B., Mimran A., Jover B. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension (2002) 40 142-148.
33. Yu W., Akishita M., Xi H., Nagai K., Sudoh N. ACEIs attenuates oxidative stress-induced endothelial cell apoptosis via P38 MAP kinase inhibitor. Clin. Chim. Acta (2006) 364 328-334.
34. Pasini A.F., Garbin U., Nava M.C. et al. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am. J. Hypertens. (2007) 20 443-450.
35. Higashi Y., Chayama K., Yoshizumi M. Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress. Curr. Med. Chem. Cardiovasc. Hematol. Agents (2005) 3 133-148.
36. Koh K.K., Quon M.J., Han S.H., Chung W.J., Lee Y., Shin E.K. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int. J. Cardiol. (2006) 108 96-100.
37. Kovacs I., Toth J., Tarjan J., Koller A. Correlation of flow mediated dilatation with inflammatory markers in patients with impaired cardiac function. Beneficial effects of inhibition of ACE. Eur. J. Heart Fail. (2006) 8 451-459.
38. Ferrario C.M., Strawn W.B. Role of the renin-angiotensin aldosterone system and proinflammatory mediators in cardiovascular disease. Am. J. Cardiol. (2006) 98 121-128.
39. Ikeda T., Sakurai J., Nakayama D. et al. Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs. Am. J. Hypertens. (2004) 17 502-506.
40. Rajagopalan S., Zannad F., Radauceanu A., Pitt B. A multicenter double-blind randomized controlled trial of a statin + angiotensin receptor blockade combination in patients with hypertension and concomitant hyperlipidemia. Circulation (2004) 110 397-402.
41. Borghi C., Prandin M.G., Costa F.V., Bacchelli S., Degli Esposti D., Ambrsioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J. Cardiovasc. Pharmacol. (2000) 35 549-555.
42. Koh K.K., Son J.W., Ahn J.Y. et al. Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension (2004) 44 180-185.
43. Brosnan C.F., Battistini L., Raine C.S., Dickson D.W., Vall A., Lee S.C. Reactive nitrogen intermediates in human neuropathology. An overview. Dev. Neurosci. (1994) 16 152-161.
44. Knowles R.G., Moncada S. Nitric oxide as a signal in blood vessels. Trends Biochem. Sci. (1992) 17 399-402.
45. Rees D.D., Palmer R.M., Schulz R., Hodson H.F., Moncada S. Characterization of three inhibition of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol. (1990) 101 746-752.
46. Ortiz M.C., Fortepiani L.A., Martinez-Salgado C. et al. Renal effects of the chronic inhibition of nitric oxide syntheses in cirrhotic rats with ascites. Nefrologia (2001) 21 556-564.